Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance
Reads0
Chats0
TLDR
Overall, echinocandin and triazole resistance rates were low; however, the fluconazole and echinOCandin coresistance among C. glabrata strains warrants continued close surveillance.Abstract:
The SENTRY Antimicrobial Surveillance Program monitors global susceptibility and resistance rates of newer and established antifungal agents. We report the echinocandin and triazole antifungal susceptibility patterns for 3,418 contemporary clinical isolates of yeasts and molds. The isolates were obtained from 98 laboratories in 34 countries during 2010 and 2011. Yeasts not presumptively identified by CHROMagar, the trehalose test, or growth at 42°C and all molds were sequence identified using internal transcribed spacer (ITS) and 28S (yeasts) or ITS, translation elongation factor (TEF), and 28S (molds) genes. Susceptibility testing was performed against 7 antifungals (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods. Rates of resistance to all agents were determined using the new CLSI clinical breakpoints and epidemiological cutoff value criteria, as appropriate. Sequencing of fks hot spots was performed for echinocandin non-wild-type (WT) strains. Isolates included 3,107 from 21 Candida spp., 146 from 9 Aspergillus spp., 84 from Cryptococcus neoformans, 40 from 23 other mold species, and 41 from 9 other yeast species. Among Candida spp., resistance to the echinocandins was low (0.0 to 1.7%). Candida albicans and Candida glabrata that were resistant to anidulafungin, caspofungin, or micafungin were shown to have fks mutations. Resistance to fluconazole was low among the isolates of C. albicans (0.4%), Candida tropicalis (1.3%), and Candida parapsilosis (2.1%); however, 8.8% of C. glabrata isolates were resistant to fluconazole. Among echinocandin-resistant C. glabrata isolates from 2011, 38% were fluconazole resistant. Voriconazole was active against all Candida spp. except C. glabrata (10.5% non-WT), whereas posaconazole showed decreased activity against C. albicans (4.4%) and Candida krusei (15.2% non-WT). All agents except for the echinocandins were active against C. neoformans, and the triazoles were active against other yeasts (MIC90, 2 μg/ml). The echinocandins and triazoles were active against Aspergillus spp. (MIC90/minimum effective concentration [MEC90] range, 0.015 to 2 μg/ml), but the echinocandins were not active against other molds (MEC90 range, 4 to >16 μg/ml). Overall, echinocandin and triazole resistance rates were low; however, the fluconazole and echinocandin coresistance among C. glabrata strains warrants continued close surveillance.read more
Citations
More filters
Journal ArticleDOI
Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America
Thomas F. Patterson,George Richard Thompson,David W. Denning,Jay A. Fishman,Susan Hadley,Raoul Herbrecht,Dimitrios P. Kontoyiannis,Kieren A. Marr,Vicki A. Morrison,M. Hong Nguyen,Brahm H. Segal,William J. Steinbach,David A. Stevens,Thomas J. Walsh,John R. Wingard,Jo Anne H. Young,John E. Bennett +16 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI
The global problem of antifungal resistance: prevalence, mechanisms, and management
TL;DR: An effective antifungal stewardship programme is essential to control drug resistance, and should incorporate rapid fungal diagnostics, therapeutic drug monitoring, and clinical intervention teams.
Journal ArticleDOI
Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species
Sarah G. Whaley,Elizabeth L. Berkow,Jeffrey M. Rybak,Andrew T. Nishimoto,Katherine S. Barker,P. David Rogers +5 more
TL;DR: This review examines azole resistance in infections caused by C. albicans as well as the emerging non-albicans Candida species C. tropicalis, C. krusei, and C. glabrata and describes the current understanding of molecular basis of azole Resistance in these fungal species.
References
More filters
Journal ArticleDOI
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Peter G. Pappas,Carol A. Kauffman,David R. Andes,Daniel K. Benjamin,Thierry Calandra,John E. Edwards,Scott G. Filler,John F. Fisher,Bart Jan Kullberg,Luis Ostrosky-Zeichner,Annette C. Reboli,John H. Rex,Thomas J. Walsh,Jack D. Sobel +13 more
TL;DR: These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections.
Book
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
John H. Rex,Clinical +1 more
TL;DR: A method for testing the susceptibility of antifungal agents to yeast that cause invasive fungal infections, including Candida spp.
Related Papers (5)
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Oliver A. Cornely,Matteo Bassetti,Thierry Calandra,Jorge Garbino,Bart Jan Kullberg,O. Lortholary,O. Lortholary,Wouter Meersseman,Murat Akova,Maiken Cavling Arendrup,S. Arikan-Akdagli,Jacques Bille,Elio Castagnola,Manuel Cuenca-Estrella,J.P. Donnelly,Andreas H. Groll,Raoul Herbrecht,William W. Hope,Henrik Jeldtoft Jensen,Cornelia Lass-Flörl,George Petrikkos,Malcolm Richardson,Emmanuel Roilides,Paul E. Verweij,Claudio Viscoli,Andrew J. Ullmann +25 more